Showing 1 - 2 results of 2 for search 'Till Milde', query time: 0.10s Refine Results
  1. 1
    Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling

    Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling by Konstantin Okonechnikov, David R. Ghasemi, Daniel Schrimpf, Svenja Tonn, Martin Mynarek, Jan Koster, Till Milde, Tuyu Zheng, Philipp Sievers, Felix Sahm, David T.W. Jones, Andreas von Deimling, Stefan M. Pfister, Marcel Kool, Kristian W. Pajtler, Andrey Korshunov

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

    Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: